QC
BIO icon

Quent Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Quent Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7K Sell
84
-3
-3% -$851 ﹤0.01% 1005
2026
Q1 		$24.3K Sell
87
-3
-3% -$864 ﹤0.01% 925
2025
Q4 		$27.3K Hold
90
– – ﹤0.01% 910
2025
Q3 		$25.2K Buy
+90
New +$24.5K ﹤0.01% 799
2025
Q2 		– Sell
-73
Closed -$17.8K – 392
2025
Q1 		$17.8K Sell
73
-15
-17% -$4.51K ﹤0.01% 789
2024
Q4 		$28.9K Sell
88
-21
-19% -$7.13K ﹤0.01% 715
2024
Q3 		$36.5K Sell
109
-148
-58% -$47K ﹤0.01% 748
2024
Q2 		$70.2K Buy
257
+9
+4% +$2.62K 0.01% 564
2024
Q1 		$85.8K Sell
248
-32
-11% -$10.5K 0.01% 522
2023
Q4 		$90.4K Buy
280
+27
+11% +$8.46K 0.01% 478
2023
Q3 		$90.7K Hold
253
– – 0.01% 433
2023
Q2 		$95.9K Hold
253
– – 0.02% 433
2023
Q1 		$121K Hold
253
– – 0.02% 374
2022
Q4 		$106K Buy
253
+5
+2% +$2.02K 0.02% 390
2022
Q3 		$103K Hold
248
– – 0.02% 368
2022
Q2 		$123K Sell
248
-12
-5% -$6.25K 0.03% 310
2022
Q1 		$146K Sell
260
-473
-65% -$285K 0.03% 340
2021
Q4 		$554K Buy
+733
New +$549K 0.12% 144

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Quent Capital's BIO Position: Q2 2026 in Review

Quent Capital reduced its Bio-Rad Laboratories Class A (BIO) stake by 3.4% in Q2 2026, selling an estimated $851 and leaving 84 shares worth $24.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1005.

Quent Capital first reported a position in BIO in Q4 2021 and has held it in 18 quarters since. The position peaked at $554K in Q4 2021. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Quent Capital held 84 shares of Bio-Rad Laboratories Class A worth $24.7K as of Q2 2026.
  • Quent Capital sold 3 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $851.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1005 holding.
  • Quent Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and has held it in 18 quarters since.
  • Quent Capital's Bio-Rad Laboratories Class A position peaked at $554K in Q4 2021.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.